Caricamento...
Pegylated liposomal doxorubicin for myeloid neoplasms
Pegylated liposomal doxorubicin (Peg-Dox) treatment resulted in a good outcome for patients with lymphoma and multiple myeloma, with reduced cardiotoxicity and an improved pharmacokinetic profile when compared to those of conventional doxorubicin. However, the use of Peg-Dox in myeloid neoplasms rem...
Salvato in:
| Pubblicato in: | Anticancer Drugs |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Lippincott Williams & Wilkins
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6749968/ https://ncbi.nlm.nih.gov/pubmed/31283544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000811 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|